How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

561 results for

Malaria Chemoprophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Chemoprophylaxis of malaria. (PubMed)

Chemoprophylaxis of malaria. 326335 1977 08 12 2013 11 21 0007-1447 1 6075 1977 Jun 11 British medical journal Br Med J Chemoprophylaxis of malaria. 1535 Johnson F A FA eng Letter England Br Med J 0372673 0007-1447 0 Hemoglobin, Sickle 886U3H6UFF Chloroquine AIM IM Chloroquine therapeutic use Hemoglobin, Sickle metabolism Humans Malaria prevention & control Plasmodium falciparum 1977 6 11 1977 6 11 0 1 1977 6 11 0 0 ppublish 326335 PMC1607227

Full Text available with Trip Pro

1977 British medical journal

62. Chemoprophylaxis of malaria. (PubMed)

Chemoprophylaxis of malaria. 837161 1977 04 30 2018 11 13 0007-1447 1 6058 1977 Feb 12 British medical journal Br Med J Chemoprophylaxis of malaria. 447 Bergson V V eng Letter England Br Med J 0372673 0007-1447 0 Antimalarials 0 Drug Combinations 88463U4SM5 Sulfadoxine Z3614QOX8W Pyrimethamine AIM IM Antimalarials administration & dosage therapeutic use Drug Combinations Humans Malaria prevention & control Pyrimethamine therapeutic use Sulfadoxine therapeutic use 1977 2 12 1977 2 12 0 1 1977 2

Full Text available with Trip Pro

1977 British medical journal

63. Chemotherapy and Chemoprophylaxis of Malaria (PubMed)

Chemotherapy and Chemoprophylaxis of Malaria 14904985 2004 02 15 2018 12 01 0007-1447 1 4758 1952 Mar 15 British medical journal Br Med J Chemotherapy and chemoprophylaxis of malaria; clinical trials in 500 cases and mass prophylaxis in a hyperendemic area. 568-74 CHAUDHURI R N RN CHAKRAVARTY N K NK RAI CHAUDHURI M N MN JANARDAN POTI S S eng Journal Article England Br Med J 0372673 0007-1447 OM Chemoprevention Humans Malaria therapy 5221:35569:224 MALARIA/therapy 1952 3 15 1952 3 15 0 1 1952 3

Full Text available with Trip Pro

1952 British medical journal

64. Chemoprophylaxis for Malaria (PubMed)

Chemoprophylaxis for Malaria 18730679 2010 06 28 2010 06 28 0008-1264 116 2 1972 Feb California medicine Calif Med Chemoprophylaxis for malaria. 51-2 Chin J J eng Journal Article United States Calif Med 0410260 0008-1264 1972 2 1 0 0 1972 2 1 0 1 1972 2 1 0 0 ppublish 18730679 PMC1518218

Full Text available with Trip Pro

1972 California Medicine

65. Falciparum malaria despite chemoprophylaxis. (PubMed)

Falciparum malaria despite chemoprophylaxis. 380749 1979 10 24 2013 11 21 0007-1447 1 6177 1979 Jun 09 British medical journal Br Med J Falciparum malaria despite chemoprophylaxis. 1565 Moody P P eng Letter England Br Med J 0372673 0007-1447 886U3H6UFF Chloroquine S61K3P7B2V Proguanil AIM IM Chloroquine adverse effects Female Fetal Diseases chemically induced Humans Malaria prevention & control Plasmodium falciparum Pregnancy Pregnancy Complications, Infectious prevention & control Proguanil

Full Text available with Trip Pro

1979 British medical journal

66. Falciparum malaria despite chemoprophylaxis. (PubMed)

Falciparum malaria despite chemoprophylaxis. 376057 1979 09 01 2013 11 21 0007-1447 1 6174 1979 May 19 British medical journal Br Med J Falciparum malaria despite chemoprophylaxis. 1351 Bentley S J SJ eng Letter England Br Med J 0372673 0007-1447 0 Drug Combinations 886U3H6UFF Chloroquine 8W5C518302 Dapsone Z3614QOX8W Pyrimethamine AIM IM Chloroquine therapeutic use Dapsone therapeutic use Drug Combinations Humans Malaria prevention & control Plasmodium falciparum Pyrimethamine therapeutic use

Full Text available with Trip Pro

1979 British medical journal

67. Malaria

and subtropical areas of the world — malaria does not occur naturally in the UK. Malaria can be imported to the UK by people who have become infected during time spent in areas where malaria is endemic. Travellers (in particular children) visiting friends and relatives are more likely than tourists to become infected with malaria as they tend to visit remote places, stay longer and are less likely to take malaria chemoprophylaxis. UK surveillance data from 2015 showed that where history of chemoprophylaxis (...) is endemic (adjusted OR 4.6, 95% CI 3.1–9.9). A literature review looking at possible risk factors for malaria deaths in travellers found that the main risk factors were: Non-use or inappropriate use of chemoprophylaxis. Older age. Male sex. Delay in seeking care. Delay in diagnosis. Incorrect treatment. Infection with P. falciparum . Non-immunity — people born in countries where malaria is endemic may have some immunity to malaria infection from continual exposure to the parasite. Immunity rapidly

2017 NICE Clinical Knowledge Summaries

68. A comparative study of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy. (PubMed)

A comparative study of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy. The benefit of malaria prophylaxis in pregnancy is threatened by emergence of Plasmodium falciparum resistance to antimalarial agents for chemoprophylaxis and treatment.This study aimed to compare the effectiveness of azithromycin (AZ) with sulphadoxine-pyrimethamine (SP) for malaria prevention.A prospective comparative study of antenatal clinic attendees at the University College (...) Hospital, Ibadan, Nigeria. Participants were randomised to receive SP or AZ.The subjects were antenatal attendees and Samples for malaria parasitaemia were collected and repeated at follow-up visits; maternal peripheral blood film, placental and cord blood samples were collected at delivery.Chi-square test and t-test in a per-protocol analysis.Of 200 participants (100 in each group), 166 (83.0%) completed the study: 86 (86.0%) of SP and 80 (80.0%) of AZ groups, respectively (P = 0.26). Four (4.7

2018 The Nigerian Postgraduate Medical Journal Controlled trial quality: uncertain

69. Co-morbidity of malnutrition with falciparum malaria parasitaemia among children under the aged 6–59 months in Somalia: a geostatistical analysis (PubMed)

MUAC measurement in surveys. Shared spatial distribution and distinct hotspots present opportunities for targeted seasonal chemoprophylaxis and other forms of malaria prevention integrated within nutrition programmes. (...) Co-morbidity of malnutrition with falciparum malaria parasitaemia among children under the aged 6–59 months in Somalia: a geostatistical analysis Malnutrition and malaria are both significant causes of morbidity and mortality in African children. However, the extent of their spatial comorbidity remains unexplored and an understanding of their spatial correlation structure would inform improvement of integrated interventions. We aimed to determine the spatial correlation between both wasting

Full Text available with Trip Pro

2018 Infectious diseases of poverty

70. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis (PubMed)

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis Chemoprophylaxis is currently the best available prevention from malaria, but its efficacy is compromised by non-adherence to medication. Here we develop a long-acting injectable formulation of atovaquone solid drug nanoparticles that confers long-lived prophylaxis against Plasmodium berghei ANKA malaria in C57BL/6 mice. Protection is obtained at plasma concentrations above 200 ng ml-1 and is causal, attributable to drug (...) activity against liver stage parasites. Parasites that appear after subtherapeutic doses remain atovaquone-sensitive. Pharmacokinetic-pharmacodynamic analysis indicates protection can translate to humans at clinically achievable and safe drug concentrations, potentially offering protection for at least 1 month after a single administration. These findings support the use of long-acting injectable formulations as a new approach for malaria prophylaxis in travellers and for malaria control in the field.

Full Text available with Trip Pro

2018 Nature communications

71. Malaria Surveillance — United States, 2015 (PubMed)

any chemoprophylaxis in 2015 (26.5%) compared with 2014 (32.5%), and adherence was poor in this group. Among the U.S residents for whom information on chemoprophylaxis use and travel region were known, 95.3% of patients with malaria did not adhere to or did not take a CDC-recommended chemoprophylaxis regimen. Among women with malaria, 32 were pregnant, and none had adhered to chemoprophylaxis. A total of 23 malaria cases occurred among U.S. military personnel in 2015. Three cases of malaria were (...) cases from 2014 to 2015 is associated with a decrease in imported cases from West Africa. This finding might be related to altered or curtailed travel to Ebola-affected countries in in this region. Despite progress in reducing malaria worldwide, the disease remains endemic in many regions, and the use of appropriate prevention measures by travelers is still inadequate.The best way to prevent malaria is to take chemoprophylaxis medication during travel to a country where malaria is endemic

Full Text available with Trip Pro

2018 MMWR Surveillance Summaries

72. The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization with Plasmodium falciparum Malaria Sporozoites (PubMed)

The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization with Plasmodium falciparum Malaria Sporozoites Long-lasting and sterile homologous protection against malaria can be achieved by the exposure of malaria-naive volunteers under chemoprophylaxis to Plasmodium falciparum-infected mosquitoes (chemoprophylaxis and sporozoite [CPS] immunization). While CPS-induced antibodies neutralize sporozoite infectivity in vitro and in vivo, antibody-mediated

Full Text available with Trip Pro

2018 Infection and immunity

73. Protection from experimental cerebral malaria with a single intravenous or subcutaneous whole-parasite immunization (PubMed)

protective as immunization with non-attenuated sporozoites under chemoprophylaxis. Both immunization regimens delayed the development of blood-stage parasites, but differences in cellular and humoral immune mechanisms were observed. Single-dose whole-parasite vaccination might serve as a relatively simple and feasible immunization approach to prevent life-threatening cerebral malaria. (...) Protection from experimental cerebral malaria with a single intravenous or subcutaneous whole-parasite immunization Cerebral malaria is a life-threatening complication of Plasmodia infection and a major cause of child mortality in Sub-Saharan Africa. We report that protection from experimental cerebral malaria in the rodent model is obtained by a single intravenous or subcutaneous whole-parasite immunization. Whole-parasite immunization with radiation-attenuated sporozoites was equally

Full Text available with Trip Pro

2018 Scientific reports

74. Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

to Brief Summary: The study is a single site, double-blind, randomized, placebo-controlled clinical trial that will assess the safety, tolerability, immunogenicity and vaccine efficacy (VE) of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in Indonesian soldiers deployed to eastern Indonesia. Condition or disease Intervention/treatment Phase Malaria Biological: PfSPZ Vaccine Biological: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis Other: Normal Saline Phase 2 Detailed (...) Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2018 Clinical Trials

75. Determinants of malaria prophylaxis among German travelers to Kenya, Senegal, and Thailand. (PubMed)

Determinants of malaria prophylaxis among German travelers to Kenya, Senegal, and Thailand. Malaria chemoprophylaxis is a mainstay of malaria prevention in travelers. Adequate pretravel advice forms the basis for efficient malaria prophylaxis. This study assessed the determinants for seeking pretravel advice and evaluated the quality of advice from each source and its influence on the patterns and outcome of malaria prophylaxis intake.In March and April 2004, a self-administered questionnaire (...) of pretravel consultation were associated with the source of information consulted. Seventy-five percent of travelers from Senegal and Kenya received DTG compliant advice compared to only 17% of travelers from areas with low malaria risk in Thailand. Travelers returning from Kenya and Senegal had used correct chemoprophylaxis in only 65 and 47% of trips, respectively. In multivariate analysis, the factors determining correct intake among Senegal and Kenya travelers were receiving pretravel advice (from

Full Text available with Trip Pro

2017 Journal of Travel Medicine

76. Remote sensing and malaria risk for military personnel in Africa. (PubMed)

Remote sensing and malaria risk for military personnel in Africa. Nonimmune travelers in malaria-endemic areas are exposed to transmission and may experience clinical malaria attacks during or after their travel despite using antivectorial devices or chemoprophylaxis. Environment plays an essential role in the epidemiology of this disease. Remote-sensed environmental information had not yet been tested as an indicator of malaria risk among nonimmune travelers.A total of 1,189 personnel from 10 (...) the missions.Age, the lack of compliance with the chemoprophylaxis, and staying in areas with an average Normalized Difference Vegetation Index higher than 0.35 were risk factors for clinical malaria.Remotely sensed environmental data can provide important planning information on the likely level of malaria risk among nonimmune travelers who could be briefly exposed to malaria transmission and could be used to standardize for the risk of malaria transmission when evaluating the efficacy of antimalaria

Full Text available with Trip Pro

2017 Journal of Travel Medicine

77. The risk of malaria in travelers to India. (PubMed)

The risk of malaria in travelers to India. Several countries have reported a decline in malaria cases imported by travelers returning from India.We collected data on imported malaria for the period 1992 to 2005 from nine countries. Traveler statistics denominator data were obtained from the Indian Ministry of Tourism.The malaria case numbers declined from 93 cases per 100,000 travelers in 1992 to 19 cases per 100,000 travelers in 2005. The proportion of Plasmodium falciparum decreased steadily (...) throughout the years. The proportion of Plasmodium vivax accounts for more than 80% of all cases of malaria in travelers to India. Deaths due to malaria were rare; only the UK and the United States reported deaths, a total of 16, between 1992 and 2005. The high-risk areas for malaria in India can be clearly identified using endemic malaria data. High-risk states are Chhattisgarh, Orissa, Jharkhand, West Bengal, Goa (mainly P vivax), and the states east of Bangladesh.The decreasing incidence of malaria

Full Text available with Trip Pro

2017 Journal of Travel Medicine

78. Variability in malaria prophylaxis prescribing across europe: a delphi method analysis. (PubMed)

Variability in malaria prophylaxis prescribing across europe: a delphi method analysis. The indications for prescribing malaria chemoprophylaxis lack a solid evidence base that results in subjectivity and wide variation of practice across countries and among professionals.European experts in travel medicine, who are members of TropNetEurop, participated in a survey conducted using the Delphi method. This technique aims at evaluating and developing a consensus through iterations (...) that improving the evidence base on efficacy and tolerability and risk of malaria for prescribing chemoprophylaxis is needed as is further discussion across Europe to achieve harmonization of prescribing practice.

Full Text available with Trip Pro

2017 Journal of Travel Medicine

79. A balanced pro-inflammatory and regulatory cytokine signature in young African children is associated with lower risk of clinical malaria. (PubMed)

A balanced pro-inflammatory and regulatory cytokine signature in young African children is associated with lower risk of clinical malaria. The effect of timing of exposure to first Plasmodium falciparum infections during early childhood on the induction of innate and adaptive cytokine responses and their contribution to the development of clinical malaria immunity is not well established.As part of a double-blind randomized placebo-controlled trial in Mozambique using monthly chemoprophylaxis (...) of age.Higher pro-inflammatory (IL-1, IL-6, TNF) and regulatory (IL-10) cytokine concentrations during the second year of life were associated with reduced incidence of clinical malaria up to 4 years of age, adjusting by chemoprophylaxis and prior malaria exposure. Significantly lower concentrations of antigen-specific TH1 (IL-2, IL-12, IFN-) and TH2 (IL-4, IL-5) cytokines by 2 years of age were measured in children under chemoprophylaxis compared to children receiving placebo (p<0.03).Selective

Full Text available with Trip Pro

2018 Clinical Infectious Diseases Controlled trial quality: uncertain

80. Scaling up malaria intervention "packages" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making. (PubMed)

and treat); (3) SUFI + indoor residual spraying (IRS); (4) SUFI + seasonal malaria chemoprophylaxis (SMC); and, (5) SUFI + SMC + IRS. This study estimates the cost effectiveness of each of these packages to provide the NMCP with data for improving allocative efficiency and programmatic decision-making.This study is a retrospective analysis for the period 2013-2014 covering all 76 Senegal districts. The yearly implementation cost for each intervention was estimated and the information was aggregated (...) Scaling up malaria intervention "packages" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making. Senegal's National Malaria Control Programme (NMCP) implements control interventions in the form of targeted packages: (1) scale-up for impact (SUFI), which includes bed nets, intermittent preventive treatment in pregnancy, rapid diagnostic tests, and artemisinin combination therapy; (2) SUFI + reactive case investigation (focal test

Full Text available with Trip Pro

2018 Malaria journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>